indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility, which could be the result of either organic heart disease or cardiac surgical procedures.
Not useful in ischemic heart disease because it increases heart rate and thus increases myocardial oxygen demand.
Direct-acting inotropic agent whose primary activity results from stimulation of the beta-adrenoceptors of the heart
Produces comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects
Does not cause the release of endogenous norepinephrine, as does dopamine
used clinically in cases of cardiogenic shock for its β1 inotropic effect in increasing heart contractility and cardiac output.
Half life 2 minutes
In human urine, the major excretion products are the conjugates of dobutamine and 3-O-methyl dobutamine